Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 17/20 | 0.62 |
| ▸ | LONP1 | P36776 | 10/20 | 0.62 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.62 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.62 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.62 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.62 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.62 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.62 |
| ▸ | PSMB11 | A5LHX3 | 8/20 | 0.62 |
| ▸ | PSMA7 | O14818 | 8/20 | 0.62 |
| ▸ | PSMA1 | P25786 | 8/20 | 0.62 |
| ▸ | PSMA2 | P25787 | 8/20 | 0.62 |
| ▸ | PSMA3 | P25788 | 8/20 | 0.62 |
| ▸ | PSMA4 | P25789 | 8/20 | 0.62 |
| ▸ | PSMA5 | P28066 | 8/20 | 0.62 |
| ▸ | PSMB4 | P28070 | 8/20 | 0.62 |
| ▸ | PSMB3 | P49720 | 8/20 | 0.62 |
| ▸ | PSMA6 | P60900 | 8/20 | 0.62 |
| ▸ | PSMA8 | Q8TAA3 | 8/20 | 0.62 |
| ▸ | PSMB7 | Q99436 | 8/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18316321 | 0.92 | PSMB5 (0.57) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL18316319 | 0.92 | PSMB5 (0.57) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL15267521 | 0.89 | PSMB5 (0.63) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL18316405 | 0.88 | PSMB5 (0.61) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL18316402 | 0.88 | PSMB5 (0.61) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL18330636 | 0.88 | PSMB5 (0.59) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL10071801 | 0.88 | PSMB5 (0.70) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL10072156 | 0.88 | PSMB5 (0.70) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL17021218 | 0.88 | PSMB5 (0.70) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| SCHEMBL4419103 | 0.88 | PSMB5 (0.70) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | BEIJING ARTIVILA BIOPHARMA CO. LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20210155658-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2016-12-22 | — | — | US | disclosed |
| US-9340559-B2 | Proteasome inhibitor delanzomib for use in the treatment of lupus | CEPHALON, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-8785418-B2 | Lyophilization cakes of proteasome inhibitors | CEPHALON, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130345174-A1 | PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS | CEPHALON, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8541590-B2 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2516449-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | Cephalon, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120035133-A1 | Lyophilization Cakes of Proteasome Inhibitors | CEPHALON FRANCE (FR) | 2012-02-09 | — | — | US | disclosed |
| WO-2011087822-A1 | PROTEASOME INHIBITORS AND PROCESSES FOR THEIR PREPARATION, PURIFICATION AND USE | CEPHALON, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368945-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885LONP1 3319/4885PSMB8 1492/4885 |
| US-20210155658-A1 | CHIRAL SPECIFIC BORON-CONTAINING COMPOUNDS AND THEIR USE IN TREATING CANCER OR AMYLOIDOSIS | TBCA, BCL3, BCL6 | PSMB5 1303/4885LONP1 3319/4885PSMB8 1492/4885 |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | PSMB1, PSMB11, PSMB7 | PSMB5 6/4885LONP1 717/4885PSMB8 14/4885 |
| US-20130345174-A1 | PROTEASOME INHIBITOR DELANZOMIB FOR USE IN THE TREATMENT OF LUPUS | PSMB5, SSB, PSMB1 | PSMB5 1/4885LONP1 394/4885PSMB8 15/4885 |
| US-11325942-B2 | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis | TBCA, BCL3, BCL6 | PSMB5 1303/4885LONP1 3319/4885PSMB8 1492/4885 |
| US-20120035133-A1 | Lyophilization Cakes of Proteasome Inhibitors | PSMB1, PSMG3, PSMB2 | PSMB5 7/4885LONP1 210/4885PSMB8 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.